VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement are significant for both the biotechnology industry and investors. By aligning with FDA's push to modernize drug development, VERAXA is positioning itself at the forefront of a regulatory shift that favors more human-relevant testing methods. This could lead to faster approvals, lower costs, and a reduced reliance on animal testing, which is increasingly important to stakeholders and the public. For a company like VERAXA, which is advancing a pipeline of complex antibody-based therapeutics, the ability to de-risk candidates earlier and more efficiently could provide a competitive edge in a crowded oncology space.
Investors and industry observers can find more details in the full press release at https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA.
VERAXA Biotech (NASDAQ: VRXA) is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, demographics, and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers.
For more information, please visit BioMedWire. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
